RE: ASCO and pharmacometrics

From: [email protected] [mailto:[email protected]] On Behalf Of Naoto Hayashi Sent: 06 April 2016 09:46 To: [email protected] Cc: nmusers <[email protected]> Subject: Re: [NMusers] ASCO and pharmacometrics Dear Joachim, Thank you so much for your reply. Their abstract instruction allows very small number of characters, and no enough room to express what we had established in this work. Although we described the unique results in the table, they probably could not understand its meaning, or the model's outcome that I was so excited has no meaning to oncologist. It seemed so nice work for me and I hope that US pharmacometrician society would communicate with ASCO people for our future. Thanks! Best regards, Naoto Hayashi, PhD 2016-04-06 15:58 GMT+09:00 Joachim Grevel <[email protected]<mailto:[email protected]>>: Dear Naoto, Your experience is also mine. For a combined TTE safety and efficacy analysis I earned the online publication. The organisers do not believe in modelling, unless it describes what is already visible in graphs and tables of raw data. This is just my personal impression. I have not been to ASCO either. Good luck, Joachim Joachim Grevel, PhD Scientific Director BAST Inc Limited Science & Enterprise Park Loughborough University Loughborough, LE11 3AQ United Kingdom Tel: +44 (0)1509 222908<tel:%2B44%20%280%291509%20222908> http://www.bastinc.eu/ From: [email protected]<mailto:[email protected]> [mailto:[email protected]<mailto:[email protected]>] On Behalf Of Naoto Hayashi Sent: 06 April 2016 02:38 To: [email protected]<mailto:[email protected]> Subject: [NMusers] ASCO and pharmacometrics Dear all, I have a question and appreciate it if somebody can answer to me. We had submitted an abstract to ASCO annual meeting presentation 2016, and its contents included a pharmacometrics work of quantitative safety profile analysis of an anticancer drug. The behave of the safety index time courses is very unique and its results showed a very high usefulness of this drug. The abstract also included the table of population PK/PD parameters that expressed its nature, and it was compared with the similar older drug safety profile and demonstrated very high safer profile quantitatively. I have some experiences to publish some articles of population PK/PD work in several clinical pharmacology journals in the past, and I was so confident for just a poster presentation in ASCO. However, the judgment was “publication only”, i.e. just presentation in online but no poster presentation and no official record of publication officially. So, my question is whether pharmacometrics work is difficult to be picked up in ASCO presentation. Or, was my work evaluated to have no worth to be presented even in poster session because the pharmacometrics works presented in ASCO are having very high level? I have never visited ASCO before, and I just want to hear opinions about how much of importance is considered for pharmacometrics work in ASCO. Thanks a lot in advance for your comments/thoughts. Best regards, Naoto Hayashi This message and any attachment are confidential and may be privileged or otherwise protected from disclosure. If you are not the intended recipient, you must not copy this message or attachment or disclose the contents to any other person. If you have received this transmission in error, please notify the sender immediately and delete the message and any attachment from your system. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not accept liability for any omissions or errors in this message which may arise as a result of E-Mail-transmission or for damages resulting from any unauthorized changes of the content of this message and any attachment thereto. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not guarantee that this message is free of viruses and does not accept liability for any damages caused by any virus transmitted therewith. Click http://www.merckgroup.com/disclaimer to access the German, French, Spanish and Portuguese versions of this disclaimer.